Triflusal

Drug Profile

Triflusal

Alternative Names: Aflen; Disgren; Tecnosal; Triflux; UR 1501

Latest Information Update: 03 Aug 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Uriach
  • Class Antiplatelets; Salicylates
  • Mechanism of Action Cyclooxygenase inhibitors; Platelet aggregation inhibitors; Thromboxane A2 synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Marketed Myocardial infarction; Thromboembolism; Unstable angina pectoris
  • Discontinued Alzheimer's disease; Dementia; Stroke

Most Recent Events

  • 03 Aug 2007 Discontinued - Phase-I for Alzheimer's disease in Europe (unspecified route)
  • 03 Aug 2007 Discontinued - Phase-I for Dementia in Europe (unspecified route)
  • 03 Aug 2007 Discontinued - Phase-II for Stroke in Argentina (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top